Drug Utilization Evaluation of Piperacillin and Tazobactum at a Tertiary Care Center in Hyderabad, India.
Drug use evaluation is an ongoing, systematic, criteria-based program of medicine evaluations that will help ensure appropriate medicine use. If therapy is determined to be inappropriate, interventions with providers or patients will be necessary to optimize pharmaceutical therapy. Empirical therapy forms the basis of treatment in India mostly and it is the responsibility of DTC (Drugs and therapeutics committee) to organize a DUE study and adopt suitable protocol for controlling irrational drug use. In our study we have developed a data collection form based upon WHO guidelines for conducting a DUE study on piperacillin and tazobactum use evaluation. To assess the usage of piperacillin and tazobactum at a tertiary care center Hyderabad compared to the indications for piperacillin and tazobactum use and standard treatment guidelines and provide recommendations to improve rational use of piperacillin and tazobactum at these hospitals and reduce the development of further antibiotic resistance, prevent ADRs associated with the drug, and to reduce the economic burden on the patient with inappropriate use. For conducting the evaluation process we had followed the standard guide lines formulated by WHO. The gender distributions of casesheets were male- 42, female- 23. Indication wise the distribution of case sheets were mostly treated for surgical prophylaxis, prophylaxis and infections. Out of 65 cases 65 (99%) has met the established criteria, they are as per STGs. Illness most frequently treated with piperacillin and tazobactum is ckd with acute deterioration (29.23%). The minimum number of days of treatment was 3 day and the maximum number of days of treatment was 14days. All patient folders evaluated with regards to HD, SEPTIC SHOCK, PNEMOMEDIATINM etc were found to meet the standard criteria appropriate for piperacillin and tazobactum use with respect to dose, and dose frequency. However, in the case of dose duration the evaluation was found to be largely inappropriate for all the justified indications.
2. Available from: www.who.int/.../tbs/11-PG_Drug-Use-Evaluation_final-08.pdf
3. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050684s055s061_050750s016s020lbl.pdf
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).